NASDAQ:INGNInogen Stock Price, Forecast & News

Inogen's stock was trading at $40.61 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, INGN stock has increased by 31.9% and is now trading at $53.56. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Inogen.

Inogen is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Inogen.

Inogen Inc (NASDAQ:INGN) released its quarterly earnings data on Tuesday, February, 25th. The medical technology company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.11 by $0.17. The medical technology company earned $78.92 million during the quarter, compared to analyst estimates of $90.11 million. Inogen had a net margin of 5.79% and a return on equity of 7.07%. The business's revenue was down 8.8% on a year-over-year basis. During the same period last year, the company earned $0.44 EPS. View Inogen's earnings history.

Inogen issued an update on its FY 2020 After-Hours earnings guidance on Tuesday, February, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $385-400 million, compared to the consensus revenue estimate of $403.47 million.

6 analysts have issued 1-year price targets for Inogen's shares. Their forecasts range from $45.00 to $90.00. On average, they expect Inogen's stock price to reach $62.00 in the next year. This suggests a possible upside of 15.8% from the stock's current price. View analysts' price targets for Inogen.

News headlines about INGN stock have been trending very negative this week, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Inogen earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned media coverage about the medical technology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutInogen.

Inogen saw a decrease in short interest in February. As of February 28th, there was short interest totaling 2,380,000 shares, a decrease of 6.3% from the February 13th total of 2,540,000 shares. Based on an average trading volume of 352,500 shares, the days-to-cover ratio is currently 6.8 days. Approximately 13.1% of the company's shares are sold short. View Inogen's Current Options Chain.

Some companies that are related to Inogen include MSA Safety (MSA), Wright Medical Group (WMGI), Wound Management Technologies (WNDM), Avanos Medical (AVNS), Establishment Labs (ESTA), Invacare (IVC), RTI Surgical (RTIX), Lakeland Industries (LAKE), Sientra (SIEN), Allied Healthcare Products (AHPI), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Histogenics (HSGX), NanoVibronix (NAOV) and Rewalk Robotics (RWLK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Medivation (MDVN), NVIDIA (NVDA), First Solar (FSLR), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU) and Square (SQ).

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Inogen's stock is owned by many different institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.07%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View institutional ownership trends for Inogen.

INGN stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch, and Loren L Mcfarland. View insider buying and selling activity for Inogen.

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INGN stock can currently be purchased for approximately $53.56.

Inogen has a market capitalization of $1.18 billion and generates $361.94 million in revenue each year. The medical technology company earns $20.95 million in net income (profit) each year or $1.07 on an earnings per share basis. Inogen employs 1,020 workers across the globe. View additional information about Inogen.

The official website for Inogen is http://www.inogen.com/.

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]